Table 1. Association between the expression level of lnc-RAB11B-AS1 and the clinic characteristics of the patients.
| Clinic characteristics | Southern samples, N (%) | Pa | Eastern samples, N (%) | Pa | Merged samples, N (%) | Pa | |||
|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | Low | High | ||||
| Age | |||||||||
| <60 | 38 (36.2) | 67 (63.8) | 0.462 | 21 (41.2) | 30 (58.8) | 0.233 | 59 (37.8) | 97 (62.2) | 0.180 |
| ≥60 | 32 (41.6) | 45 (58.4) | 23 (53.5) | 20 (46.5) | 55 (45.8) | 65 (54.2) | |||
| Sex | |||||||||
| Female | 23 (44.2) | 29 (55.8) | 0.312 | 15 (53.6) | 13 (46.4) | 0.392 | 38 (47.5) | 42 (52.5) | 0.182 |
| Male | 47 (36.2) | 83 (63.8) | 29 (43.9) | 37 (56.1) | 76 (38.8) | 120 (61.2) | |||
| Family history of cancer | |||||||||
| No | 92 (38.5) | 99 (61.5) | 0.971 | 40 (47.6) | 44 (52.4) | 0.648 | 102 (41.6) | 143 (58.4) | 0.755 |
| Yes | 8 (38.1) | 13 (61.9) | 4 (40.0) | 6 (60.0) | 12 (38.7) | 19 (61.3) | |||
| Family history of lung cancer | |||||||||
| No | 64 (37.9) | 105 (62.1) | 0.554 | 44 (48.4) | 47 (51.6) | 0.099 | 108 (41.5) | 152 (58.5) | 0.750 |
| Yes | 6 (46.2) | 7 (53.8) | 0 (0) | 3 (100.0) | 6 (37.5) | 10 (62.5) | |||
| Smoking | |||||||||
| No | 32 (47.8) | 35 (52.2) | 0.049 | 15 (50.0) | 15 (50.0) | 0.671 | 47 (48.5) | 50 (51.5) | 0.076 |
| Yes | 38 (33.0) | 77 (67.0) | 29 (45.3) | 35 (54.7) | 67 (37.4) | 112 (62.6) | |||
| Drinking | |||||||||
| No | 53 (38.7) | 84 (61.3) | 0.913 | 38 (52.1) | 35 (47.9) | 0.057 | 91 (43.3) | 119 (56.7) | 0.222 |
| Yes | 17 (37.8) | 28 (62.2) | 6 (28.6) | 15 (71.4) | 23 (34.8) | 43 (65.2) | |||
| Surgery | |||||||||
| No | 46 (38.0) | 75 (62.0) | 0.862 | 28 (48.3) | 30 (51.7) | 0.717 | 74 (41.3) | 105 (58.7) | 0.987 |
| Yes | 24 (39.3) | 37 (60.7) | 16 (44.4) | 20 (55.6) | 40 (41.2) | 57 (58.8) | |||
| Chemotherapy | |||||||||
| No | 21 (33.3) | 42 (66.7) | 0.301 | 10 (34.5) | 19 (65.5) | 0.110 | 31 (33.7) | 61 (66.3) | 0.069 |
| Yes | 49 (41.2) | 70 (58.8) | 34 (52.3) | 31 (47.7) | 83 (45.1) | 101 (54.9) | |||
| Radiotherapy | |||||||||
| No | 43 (41.3) | 61 (58.7) | 0.356 | 18 (37.5) | 30 (62.5) | 0.065 | 61 (40.1) | 91 (59.9) | 0.661 |
| Yes | 27 (34.6) | 51 (65.4) | 26 (56.5) | 20 (43.5) | 53 (42.7) | 71 (57.3) | |||
| Clinical stages | |||||||||
| I + II | 44 (62.0) | 27 (38.0) | <0.001 | 20 (69.0) | 9 (31.0) | 0.004 | 64 (64.0) | 36 (36.0) | <0.001 |
| III + IV | 26 (23.4) | 85 (61.5) | 24 (36.9) | 41 (63.1) | 60 (34.1) | 116 (65.9) | |||
| T | |||||||||
| 1+2 | 43 (41.4) | 61 (58.6) | 0.356 | 23 (51.1) | 22 (48.9) | 0.423 | 66 (44.3) | 83 (55.7) | 0.274 |
| 3+4 | 27 (34.6) | 51 (65.4) | 21 (42.9) | 28 (57.1) | 48 (37.8) | 79 (62.2) | |||
| N | |||||||||
| 0 | 34 (51.5) | 32 (48.5) | 0.006 | 27 (62.8) | 16 (37.2) | 0.004 | 61 (56.0) | 48 (44.0) | <0.001 |
| 1+2+3 | 36 (31.0) | 80 (69.0) | 17 (33.3) | 34 (66.7) | 53 (31.7) | 114 (68.3) | |||
| M | |||||||||
| 0 | 62 (48.1) | 67 (51.9) | <0.001 | 33 (55.0) | 27 (45.0) | 0.034 | 95 (50.3) | 94 (49.7) | <0.001 |
| 1 | 8 (15.1) | 45 (84.9) | 11 (32.4) | 23 (67.6) | 19 (21.8) | 68 (78.2) | |||
| Histological types | |||||||||
| Adenocarcinoma | 37 (43.0) | 49 (57.0) | 0.325 | 20 (48.8) | 21 (51.2) | 0.471 | 57 (44.9) | 70 (55.1) | 0.747 |
| Squamous cell carcinoma | 21 (41.2) | 30 (58.8) | 12 (38.7) | 19 (61.3) | 33 (40.2) | 49 (59.8) | |||
| Large cell carcinoma | 1 (16.7) | 5 (83.3) | 2 (40.0) | 3 (60.0) | 3 (27.3) | 8 (72.7) | |||
| Small cell lung cancer | 4 (21.1) | 15 (78.9) | 6 (75.0) | 2 (25.0) | 10 (37.0) | 17 (63.0) | |||
| Other carcinomasb | 7 (35.0) | 13 (65.0) | 4 (44.4) | 5 (55.6) | 11 (37.9) | 18 (62.1) | |||
a, Pearson χ2 test P value; b, mixed-cell or undifferentiated carcinoma.